Our Journey Beyond Sunset Boulevard : : evidence-based analysis of tumor-targeted gene- & immuno-therapies shine a critical spotlight on "true" long-term cancer-free survival / / by Erlinda M. Gordon and Frederick L. Hall.
The revival of DeltaRex-G (formerly Rexin-G)-the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history-returned active tumor surveillance and a precision-guided "silver bullet" (dnG1 killer gene) to the cancer clinic with "Expanded Access" in 2019. Empow...
Saved in:
| VerfasserIn: | |
|---|---|
| TeilnehmendeR: | |
| Place / Publishing House: | London : : IntechOpen,, 2021. ©2021 |
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 online resource (xii, 56 pages) :; illustrations |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 02139nam a2200325 i 4500 | ||
|---|---|---|---|
| 001 | 993603248204498 | ||
| 005 | 20230629171457.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 230629s2021 enka o 000 0 eng d | ||
| 035 | |a (CKB)5400000000042264 | ||
| 035 | |a (NjHacI)995400000000042264 | ||
| 035 | |a (EXLCZ)995400000000042264 | ||
| 040 | |a NjHacI |b eng |e rda |c NjHacl | ||
| 050 | 4 | |a RC271.G45 |b .G673 2021 | |
| 082 | 0 | 4 | |a 616.994042 |2 23 |
| 100 | 1 | |a Gordon, Erlinda M., |e author. | |
| 245 | 1 | 0 | |a Our Journey Beyond Sunset Boulevard : |b evidence-based analysis of tumor-targeted gene- & immuno-therapies shine a critical spotlight on "true" long-term cancer-free survival / |c by Erlinda M. Gordon and Frederick L. Hall. |
| 246 | |a Our Journey Beyond Sunset Boulevard | ||
| 264 | 1 | |a London : |b IntechOpen, |c 2021. | |
| 264 | 4 | |c ©2021 | |
| 300 | |a 1 online resource (xii, 56 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | |a Description based on publisher supplied metadata and other sources. | ||
| 520 | |a The revival of DeltaRex-G (formerly Rexin-G)-the first proactive tumor-hunting/tumor-killing biomedicine of this kind in history-returned active tumor surveillance and a precision-guided "silver bullet" (dnG1 killer gene) to the cancer clinic with "Expanded Access" in 2019. Empowered by US Right-to-Try legislation, while honoring ethical principles of "informed consent," this unique graphic/picturesque presentation of clinical and translational medicine is intended for postmodern (post-Enlightenment) layman readers, including cancer patients, students, researchers, and future practitioners in the field of precision gene-based medicine. Confronting logical fallacies in popular opinion, the authors present newsworthy, up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors-validating "pathotropic" (disease-seeking) tumor targeting avant la lettre. | ||
| 650 | 0 | |a Drug delivery systems. | |
| 650 | 0 | |a Cancer |x Immunotherapy. | |
| 650 | 0 | |a Cancer |x Gene therapy. | |
| 776 | |z 1-83969-417-3 | ||
| 700 | 1 | |a Hall, Frederick L., |e author. | |
| 906 | |a BOOK | ||
| ADM | |b 2023-07-08 12:11:10 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5351667070004498&Force_direct=true |Z 5351667070004498 |b Available |8 5351667070004498 | ||